OCUL
Ocular Therapeutix, Inc. (OCUL) Scenario Analysis Analysis (2026)
Overall Score
Balance Sheet
Very strong liquidity with a current ratio of 13.1x and cash ratio of 12.2x.
Low leverage with debt-to-equity of 0.15x and debt-to-assets of 0.12x.
Net debt remains manageable relative to EBITDA despite negative operating earnings.
Profitability
Gross margin is high at 87.1%, showing strong product-level economics.
Operating and net margins remain deeply negative at -6.0% and -5.8%, respectively.
Returns are still poor, with ROE at -59.9% and ROIC at -50.2%.
Cash Flow
Free cash flow remains negative, with FCF yield at -11.5% and FCF-to-EBITDA still negative.
Operating cash flow is negative, indicating the core business is not yet self-funding.
Income quality is reasonable at 0.79, suggesting reported earnings are not overly distorted.
Valuation
Valuation remains rich at 32.8x EV/sales and 42.8x price/sales.
Negative earnings and cash flow make traditional earnings and FCF multiples less meaningful.
The balance sheet provides some support, but the stock still prices in substantial future improvement.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Ocular Therapeutix, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

